Results of these studies demonstrated specific homing of the NK cells to the tumor sites, a reduction in the number of metastases and significant tumor regression, indicating that this could constitute a promising therapeutic approach for HER2+ GC. The gene discussed is ERBB2; the disease is neoplasm.